In December 1975, the West Midlands Regional Health Authority recorded difficulties in producing sufficient plasma and it was agreed that commercial Factor 8 (Kryobulin) would need to be purchased at an annual cost to the region of £350,000. Read more about In December 1975, the West Midlands Regional Health Authority recorded difficulties in producing sufficient plasma and it was agreed that commercial Factor 8 (Kryobulin) would need to be purchased at an annual cost to the region of £350,000.
The West Midlands Regional Health Authority Working Party on the Treatment of Haemophiliacs met regularly throughout the 1970s to discuss issues relating to supply Read more about The West Midlands Regional Health Authority Working Party on the Treatment of Haemophiliacs met regularly throughout the 1970s to discuss issues relating to supply
In 1976 Dr Frank Hill succeeded Dr Jillian Mann as director at the Children's Hospital; Dr John Stuart was director at QEH until 1983 when he was succeeded by Dr Ian Franklin Read more about In 1976 Dr Frank Hill succeeded Dr Jillian Mann as director at the Children's Hospital; Dr John Stuart was director at QEH until 1983 when he was succeeded by Dr Ian Franklin
In Birmingham, Haemophilia care was split between the Children's Hospital and the Queen Elizabeth Hospital. They were jointly designated as a haemophilia centre in the 1970s Read more about In Birmingham, Haemophilia care was split between the Children's Hospital and the Queen Elizabeth Hospital. They were jointly designated as a haemophilia centre in the 1970s
Professor Eric Preston stated in his statement that cryoprecipitate was not a treatment option for severe haemophiliacs, and that this did not change over time. Read more about Professor Eric Preston stated in his statement that cryoprecipitate was not a treatment option for severe haemophiliacs, and that this did not change over time.
In 1980, in the Sheffield Haemophilia Centre, a small amount of cryoprecipitate was used, but the majority of treatment was commercial concentrate (4,690 units of cryoprecipitate; 141,775 units of NHS concentrate; 800,852 units of commercial concentrates (Factorate, Hemofil, Kryobulin)). Read more about In 1980, in the Sheffield Haemophilia Centre, a small amount of cryoprecipitate was used, but the majority of treatment was commercial concentrate (4,690 units of cryoprecipitate; 141,775 units of NHS concentrate; 800,852 units of commercial concentrates (Factorate, Hemofil, Kryobulin)).
Annual returns for Sheffield Haemophilia Centre in 1980 recorded that a small amount of cryoprecipitate was used, but the mainstay of treatment was commercial concentrate Read more about Annual returns for Sheffield Haemophilia Centre in 1980 recorded that a small amount of cryoprecipitate was used, but the mainstay of treatment was commercial concentrate
In 1979 the Sheffield Haemophilia Centre's return recorded no cryoprecipitate use at all for people with Haemophilia A. Read more about In 1979 the Sheffield Haemophilia Centre's return recorded no cryoprecipitate use at all for people with Haemophilia A.
It was noted in the Annual Returns for Sheffield Haemophilia Centre for 1977 'that "home treatment packs' from ARMOUR have been used most of the time for home therapy." Read more about It was noted in the Annual Returns for Sheffield Haemophilia Centre for 1977 'that "home treatment packs' from ARMOUR have been used most of the time for home therapy."
The annual return for 1976 showed the Sheffield Haemophilia Centre treating its patients with cryoprecipitate, NHS Factor 8 and commercial concentrates. Read more about The annual return for 1976 showed the Sheffield Haemophilia Centre treating its patients with cryoprecipitate, NHS Factor 8 and commercial concentrates.